• Chemistry Analysis
  • Separation Center
  • Center of Natural Product
  • Impurity Isolation and Identification
  • Physicochemical Characterization & Others
  • Pharmaceutical Analysis
  • ASMS Screening
  • Biology
  • In vitro Biology
  • Enzymes/Biochemical Assays
  • Ion Channel
  • Cellular Assays
  • GPCR, Transporter and NHR
  • Radioactive Assays
  • Cancer Cell Panel & In Vitro Oncology Assays
  • In Vitro Assays for Diabetes and Other Metabolic Diseases
  • High Throughput Screening
  • High Content Platform
  • Protein Expression and Purification
  • In vivo Pharmacology & PK/PD
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Fibrosis: Lung, Liver, Kidney
  • Central Nervous System & Pain
  • Respiratory: Asthma & COPD
  • IBS/IBD Animal Models
  • Large Animal Disease Models
  • Infectious Disease
  • Antiviral Services
  • Virology Assays Supporting Human Clinical Trials
  • Antibacterial In Vitro Screening and Pharmacology Services
  • HBV Platform
  • Safety and Early Toxicity
  • In Vitro Safety Profiling for Medchem Support
  • In Vitro Tox Assays for Medchem Support
  • Early Stage Safety Assessment
  • Oncology & Immunology
  • CRISPR/Cas9 Gene Editing
  • In Vitro & In Vivo Library Screening
  • In Vivo CRISPR Animal Models and Services
  • Gene Therapy
  • Tumor Models
  • Cell Line-Derived Xenograft (CDX) Tumor Models
  • Patient-Derived Xenograft (PDX) Tumor Models
  • Syngeneic Tumor Models
  • Human Immune Checkpoint Gene KI Mouse Models
  • hPBMC/HSC Humanized Models
  • Immuno-oncology
  • Translational Oncology
  • Biomarker
  • Discovery Biomarker
  • Clinical Biomarker
  • Autoimmune and Inflammatory Animal Models
  • OncoWuXi Database
  • Structure Based Drug Discovery
  • Protein Production
  • X-ray Crystallography
  • CryoEM
  • Biophysical Assays and Screening
  • FBDD - Fragment Screening
  • Biopharmaceutical Assays
  • Crelux
  • HD Biosciences
  • About Us
  • About WuXi RSD
  • RSD Leadership
  • About WuXi AppTec
  • News & Events
  • News
  • Upcoming Events
  • Resource Library
  • Newsletters
  • Latest Sciences
  • Literature Download
  • Contact
  • CN
    Cardiovascular Diseases

    In Vitro Services for Cardiovascular and Metabolic Diseases (CMD)

    Service Provided

  • Assay development and execution
  • Compound screening and profiling
  • Medicinal chemistry program support
  • Mechanism of action (MOA) studies
  • Target Family

  • GPCR/Receptor
  • Enzyme
  • Transporter
  • Antibody
  • Biomarker
  • Technology Platforms available

  • Radioactivity assays
  • Fluorescence assays
  • Luminescence assays
  • Electochemiluminescence assays
  • PCR
  • Western blot
  • Isoelectric focusing electrophoresis (IEF)
  • SPR (Biacore), ITC
  •  

    In Vivo Services for Cardiovascular and Metabolic Disease (CMD)

    Obesity

  • Acute food intake, chronic food intake and body weight studies, breeding or establishing diet induced obesity mice, multiple clinical readouts
  • Diabetes

  • oGTT (mouse/rat), ipGTT (mouse/rat), ivGTT (rat), glucosuria
  • Chronic efficacy studies in db/db and other hyperglycemic models, chronic efficacy studies for improvement of insulin sensitivity
  • DIO/STZ mice
  • Dyslipidemia

  • Acute lipid tolerance
  • Chronic studies to monitor triglycerides, cholesterol
  • Hypertension

  • Blood pressure measurement in telemetrized rats
  • (Na/K) diuresis
  • Nephropathy

  • Proteinuria, natriuresis
  • Podocyte-induced kidney injury
  • Cisplatin-induced kidney injury
  • Thrombosis

  • Rat arteriovenous shunt model
  • Rat tail bleeding model
  •  

    In Vivo Anti-Hypertension Service

    The General Pharmacology team at WuXi Biology offers in vivo screening and testing for the pharmacological effects of anti-hypertension candidates for our clients using wireless remote systems in free moving awake animals (including rodents and large animals). Several candidates have been approved by CFDA/FDA in 2016-2017 referencing studies carried out in our laboratories.

    Introduction: Use DSI telemetry system in SHR, salt sensitive (DSS, DOCA) or angiotensin II-induced hypertension animals to evaluate anti-hypertension candidates

    Species: rat, dogs, NHP

    Endpoint: MBP, SBP, DBP, HR, ECG

    Turnaround time:  4~8weeks/study

     

    Cardiovascular Disease Animal Models

  • Myocardial infarction/reperfusion induced Heart Failure
  • Atherosclerosis
  • Pulmonary Hypertension
  • Middle Cerebral Artery Occlusion
  •  

    Others

  • AV-shunt
  • Tail bleeding
  • Coagulation test(PT,APTT,TT,FIB)
  • Platelet aggregation
  • Safety pharmacology
  • Telemetry BP recording system
  •  

    Business Contact 

  • North America: Declan Ryan,  declan.ryan@wuxiapptec.com
  • Europe and Israel: Dave Madge,  dave_madge@wuxiapptec.com
  • China: Marcher Xu,  xu_longji@wuxiapptec.com
  • Japan: Yan Zhu,  yan_zhu@wuxiapptec.com
  • Korea: Suk Young Cho,  sycho@wuxiapptec.com